On its website, Fox News 
(8/8, Grush) reports, "A new study from the University of Chicago
Medicine revealed patients taking sirolimus receive more of its
anti-cancer benefits if they drink a glass of grapefruit juice every day
along with the drug."
(8/8, Grush) reports, "A new study from the University of Chicago
Medicine revealed patients taking sirolimus receive more of its
anti-cancer benefits if they drink a glass of grapefruit juice every day
along with the drug."
On its website, NBC News
/LiveScience (8/8, Wanjek) reports that investigators "conducted a
study on 138 people with incurable cancers to determine an ideal dose."
One "third received only sirolimus; a third took sirolimus with eight
ounces of grapefruit juice; and a third took sirolimus with another
drug, called ketoconazole, which also increases sirolimus' absorption."
The investigators "found that the optimal cancer-fighting dose for
those taking only sirolimus was about 90 mg
per week, twice as high as the side-effect threshold."
/LiveScience (8/8, Wanjek) reports that investigators "conducted a
study on 138 people with incurable cancers to determine an ideal dose."
One "third received only sirolimus; a third took sirolimus with eight
ounces of grapefruit juice; and a third took sirolimus with another
drug, called ketoconazole, which also increases sirolimus' absorption."
The investigators "found that the optimal cancer-fighting dose for
those taking only sirolimus was about 90 mg
per week, twice as high as the side-effect threshold."
On its website, the ABC News
(8/8, Lupkin) "Medical Unit" blog reports that the juice increased
"sirolimus levels by 350 percent and lowering the necessary doses from
90 mg per week to between 25 and 35 mg per week."
(8/8, Lupkin) "Medical Unit" blog reports that the juice increased
"sirolimus levels by 350 percent and lowering the necessary doses from
90 mg per week to between 25 and 35 mg per week."
HealthDay
(8/8, Reinberg) points out that "early studies suggest that sirolimus
may have tumor-fighting effects. Derivatives of the drug are used in
kidney cancer and breast cancer." The study, which received funding
from the National Institutes of Health, was published in Clinical Cancer
Research.
(8/8, Reinberg) points out that "early studies suggest that sirolimus
may have tumor-fighting effects. Derivatives of the drug are used in
kidney cancer and breast cancer." The study, which received funding
from the National Institutes of Health, was published in Clinical Cancer
Research.
No comments:
Post a Comment